Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 - 39 years inclusive~* Provide written informed consent to participate~* Healthy participants without acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality~  o As determined by medical history, physical exam, laboratory screening~* Body Mass Index 18-35 kg/m2, inclusive, at screening~Exclusion Criteria:~* Any medical condition that in the judgement of the investigator would make subject participation in the study unsafe.~* Having cancer or received treatment for cancer within three years (persons with a history of cancer who are disease-free without treatment for three years or more are eligible), excluding basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), which are allowed unless located at the vaccination site.~* Impaired immune responsiveness (of any cause), including diabetes mellitus.~* Receipt or plan to receive a non-study vaccine within 30 days prior to vaccination or 60 days after vaccination.~* Receipt of any influenza vaccine in previous 24 months and/or planned receipt of influenza vaccine for the duration of the study.~* Diagnosed influenza infection in the previous 24 months prior to screening.~* Diagnosed COVID infection via medical personnel or at home test within the past 60 days prior to screening~* Allergy to influenza vaccine or components, or history of severe local or systemic reaction to any vaccination.~* History of anaphylactic type reaction to injected vaccines~* History of or current allergy to latex~* History of Guillain-Barré Syndrome.~* Positive test result for hepatitis B surface antigen (HBsAg,), hepatitis C virus antibody (HBcAb), or human immunodeficiency virus (HIV) types 1 or 2 antibodies at screening.~* History of chronic obstructive pulmonary disease or history of other lung disease.~* History of severe allergic reactions to eggs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- 15 μg of the H1 influenza antigen (Type: ACTIVE_COMPARATOR): None
- 7.5 μg of the H1 influenza antigen (Type: ACTIVE_COMPARATOR): None
- Placebo (no antigen) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).